Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Chasing a cellular fountain of youth

Nature Biotechnology volume 23, pages 807–815 (2005)Cite this article

An Erratum to this article was published on 01 October 2005

Biotech companies with business models as diverse as the products they are developing are laboring to move cell-based therapies into the clinic. Without a commercial success, however, investors will remain on the sidelines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Finding the needle in the haystack.
Figure 2: Road to clinic.

References

  1. Dove, A. Cell-based therapies go live. Nat. Biotechnol. 20, 339–343 (2002).

    Article  CAS  Google Scholar 

  2. Bouchie, A. Tissue engineering firms go under. Nat. Biotechnol. 20, 1178–1179 (2002).

    Article  CAS  Google Scholar 

  3. Pearson, H. Early embryos fuel hopes for shortcut to stem-cell creation. Nature 432, 4 (2004).

    Article  CAS  Google Scholar 

  4. Keller, G. & Snodgrass, H.R. Human embryonic stem cells: the future is now. Nat. Med. 5, 151–152 (1999).

    Article  CAS  Google Scholar 

  5. Regalado, A. Big companies quietly pursue research on embryonic stem cells. The Wall Street Journal, April 12 (2005), p. A1.

  6. Louet, S. Reagent safety issues surface for cell/tissue therapies. Nat. Biotechnol. 22, 253–254 (2004).

    Article  CAS  Google Scholar 

  7. Keirstead, H. et al. Oligodendrocyte progenitor transplants and spinal cord injury. J. Neurosci. 25, 4766–4778 (2005).

    Article  Google Scholar 

  8. Bassett, P. Cell Therapy Technologies, Markets, & Opportunities (Drug & Market Development Publications, Westborough, Massachusetts, January, 2003). http://www.drugandmarket.com/9086

    Google Scholar 

Download references

Author information

Author notes

  1. Ken Howard is a contributing writer based in Westborough, MA. Stephan Herrera is news editor at Nature Biotechnology, and Christopher Thomas Scott is a writer and author based in San Francisco, CA. His latest book, The Stem Cell, will be in bookstores September 1, 2005.

    Authors
    1. Ken Howard Wilan
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Christopher Thomas Scott
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Stephan Herrera
      View author publications

      You can also search for this author in PubMed Google Scholar

    Related links

    Related links

    Related links in Nature Research

    Licensing fees slow advance of stem cells

    Korean team lauded for stem-cell advance

    Stem-cell therapies: The first wave

    Web links

    US National Institutes of Health Stem Cell Registry

    Waisman Center at the University of Wisconsin

    California Institute of Regenerative Medicine

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Wilan, K., Scott, C. & Herrera, S. Chasing a cellular fountain of youth. Nat Biotechnol 23, 807–815 (2005). https://doi.org/10.1038/nbt0705-807

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/nbt0705-807

    This article is cited by

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing